To support clinical development of HCV non-structural protein (NS) 3 protease inhibitors (PIs), phenotypic monitoring of patient isolates is a prerequisite for understanding the emergence of resistance. HCV isolates typically fail to replicate in cell culture, necessitating the use of alternative phenotyping methods.
Methods
An NS3 protease chimeric replicon system was developed to monitor the phenotype of clinical isolates. The transfer of NS3 protease domain sequences from HCV-infected patients to the background of genotype (Gt) 1a-H77c, 1b-Con1 and 2a-JFH-1 lab strain replicons adapted to high-level cell culture replication was investigated.
Results
NS3 protease sequences derived from HCV Gt 1a or Gt 1b infected patients were transferred into Gt 1a and 1b replicons, respectively. Replication was detected for 20% of Gt 1a and 75% of Gt 1b sequences. Incorporation of known cell culture adaptive change NS3-E176G improved replication of Gt 1b but not of Gt 1a sequences. Transfer of Gt 1a clinical sequences into the Gt 1b background enhanced replication and allowed phenotypic analysis of all sequences. A correlation was observed between clinical isolate sequence polymorphisms and reduced susceptibility to NS3 PI. In mixed populations containing known NS3 PI resistance changes NS3-R155K or D168E/V, sensitivity of resistance detection was ≥10%.
Conclusions
An HCV replicon capable of supporting phenotypic characterization of patient-derived HCV NS3 protease sequences was developed. Pre-existence of amino acid changes associated with NS3 PI resistance highlights the need for combination therapies in the treatment of HCV.
References
1.
ChooQ.L., KuoG., WeinerA.J.Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244: 359–362.
2.
LavanchyD.The global burden of HCV. Liver Int2009; 29: 74–81.
3.
FosterG.R.Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat2009; 16: 605–611.
4.
MannsM.P., McHutchisonJ.G., GordonS.C.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 358: 958–965.
5.
FriedM.W., ShiffmanM.L., ReddyR.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
6.
KwongA.D., McNairL., JacobsonI.Recent progress in the development of seleted hepatitis C virus NS3-4A protease and NS5B inhibitors. Curr Opin Pharmacol2008; 8: 522–531.
7.
HézodeC., ForestierN., DusheikoG.Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med2009; 360: 1839–1850.
8.
SarrazinC., RouzierR., WagnerF.SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology2007; 132: 1270–1278.
9.
SusserS., WelschC., WangY.Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology2009; 50: 1709–1718.
10.
López-LabradorF.X., MoyaA., Gonzàlez-CandelasF.Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther2008; 13: 481–494.
11.
CuberoM., EstebanJ.I., OteroT.Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology2008; 370: 237–245.
12.
KuntzenT., TimmJ., BericalA.Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology2008; 48: 1769–1778.
13.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A PIs in treatment-naive subjects. J Infect Dis2008; 198: 800–807.
14.
WakitaT., PietschmannT., KatoT.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med2005; 11: 791–796.
15.
LindenbachB.D., EvansM.J., SyderA.J.Complete replication of hepatitis C virus in cell culture. Science2005; 309: 623–626.
16.
YiM., VillanuevaR.A., ThomasD.L.Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A2006; 103: 2310–2315.
17.
BartenschlagerR., SparacioS.Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res2007; 127: 195–207.
18.
QiX., BaeA., LiuS.Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res2009; 81: 166–173.
DrexlerD., BarlowD.J., FalkP.Development of an on-line automated sample clean-up method and liquid chromatography–tandem mass spectrometry analysis: application in an in vitro proteolytic assay. Anal Bioanal Chem2006; 384: 1145–1154.
21.
YanagiM., PurcellR.H., EmersonS.U.Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A1997; 94: 8738–8743.
22.
KriegerN., LohmannV., BartenschlagerR.Enhancement of hepatitis C virus RNA replication by cell culture adaptive mutations. J Virol2001; 75: 4614–4624.
23.
VerbeeckJ., StanleyM.J., ShiehJ.Evaluation of versant hepatitis C virus Gt assay (LiPA) 2.0. J Clin Microbiol2008; 46: 1901–1906.
SarrazinC., KiefferT.L., BartelsD.Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology2007; 132: 1767–1777.
26.
ZhouY., MuhU., JanzelkaB.L.Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VS-950) and interferon alpha. J Biol Chem2007; 282: 22619–22628.
27.
McPheeF., GoodA.C., CampbellJ.A.Discovery and early development of the HCV NS3 protease inhibitor BMS-605339. HepDART. 6-10 December 2009, Kohala Coast, HI, USA. Abstract 55.
28.
ImhofI., SimmondsP.Development of an intergenotypic hepatitis C virus cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol2010; 84: 4597–4610.
29.
LinC., LinK., LuongY.P.In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem2004; 279: 17508–17514.
30.
ThibeaultD., BousquetC., GingrasR.Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN-2061. J Virol2004; 78: 7352–7359.
31.
LenzO., VerbinnenT., LinT-I. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother2010; 54: 1878–1887.
32.
ChaseR., SkeltonA., XiaE.A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res2009; 84: 178–184.
33.
McCownM.F., RajyaguruS., Le PogamS.The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother2008; 52: 1604–1612.
34.
MiddletonT., HeY., Pilot-MatiasT.A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods2007; 145: 137–145.
